Holen Sie sich die Stockscreener-App
5.13
1.72%
-0.09
Handel nachbörslich:
5.07
-0.06
-1.17%
Schlusskurs vom Vortag:
$5.22
Offen:
$5.03
24-Stunden-Volumen:
575.09K
Relative Volume:
0.77
Marktkapitalisierung:
$281.61M
Einnahmen:
$124.00K
Nettoeinkommen (Verlust:
$-49.99M
KGV:
-3.0355
EPS:
-1.69
Netto-Cashflow:
$-31.03M
1W Leistung:
-8.39%
1M Leistung:
-7.73%
6M Leistung:
-2.84%
1J Leistung:
-1.16%
1-Tages-Spanne:
$5.03
$5.27
1-Wochen-Bereich:
$5.03
$5.80
52-Wochen-Spanne:
$3.785
$14.60
Candel Therapeutics Inc Stock (CADL) Company Profile
Firmenname
Candel Therapeutics Inc
Sektor
Branche
Telefon
617-916-5445
Adresse
117 KENDRICK STREET, NEEDHAM
Vergleichen Sie CADL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CADL
Candel Therapeutics Inc
|
5.13 | 286.55M | 124.00K | -49.99M | -31.03M | -1.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.67 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
628.00 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
423.47 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
831.48 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
182.77 | 39.72B | 447.02M | -1.18B | -906.14M | -6.1812 |
Candel Therapeutics Inc Stock (CADL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-28 | Eingeleitet | Stephens | Overweight |
| 2025-09-03 | Herabstufung | BofA Securities | Buy → Neutral |
| 2025-06-30 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-02-20 | Eingeleitet | Citigroup | Buy |
| 2025-02-19 | Eingeleitet | Canaccord Genuity | Buy |
| 2025-02-07 | Eingeleitet | BofA Securities | Buy |
| 2022-12-02 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-08-23 | Eingeleitet | Credit Suisse | Outperform |
| 2021-08-23 | Eingeleitet | Jefferies | Buy |
| 2021-08-23 | Eingeleitet | UBS | Buy |
Alle ansehen
Candel Therapeutics Inc Aktie (CADL) Neueste Nachrichten
Candel Therapeutics to present phase 3 prostate cancer trial data at SITC - Investing.com Nigeria
Small cap wrap: Candel Therapeutics, North Bay Resources, 374Water, Ocean Power Technologies… - Proactive financial news
Candel Therapeutics to highlight immunotherapy advances at SITC 2025 - Proactive financial news
Candel Therapeutics Presents Innovative Immunotherapy Data at SITC 2025 Annual Meeting - Quiver Quantitative
Candel Therapeutics Showcases Immunotherapy Leadership at SITC 2025, Demonstrating Integration of Clinical Innovation, Multi-Omics, and Artificial Intelligence to Advance Next-Generation Immunotherapies in Solid Tumors - The Manila Times
Candel Therapeutics Showcases Immunotherapy Leadership at SITC 2025, Demonstrating Integration of Clinical Innovation, Multi-Omics, and Artificial Intelligence to Advance Next-Generation Immunotherapies in Solid Tumors - GlobeNewswire Inc.
Can Candel Therapeutics Inc. stock weather global recessionWeekly Profit Analysis & Technical Pattern Recognition Alerts - newser.com
How Candel Therapeutics Inc. stock performs in stagflationQuarterly Portfolio Report & Expert Approved Momentum Ideas - newser.com
Candel Therapeutics to present at Jefferies Global Healthcare Conference - Proactive financial news
How geopolitical tensions affect Candel Therapeutics Inc. stock2025 Market Overview & Free Accurate Trade Setup Notifications - newser.com
Can volume confirm reversal in Candel Therapeutics Inc.CEO Change & Daily Entry Point Alerts - newser.com
What the charts say about Candel Therapeutics Inc. todayTrade Signal Summary & Capital Efficient Trading Techniques - newser.com
Will Candel Therapeutics Inc. stock reach all time highs in 20252025 Biggest Moves & AI Powered Market Entry Strategies - newser.com
Candel Therapeutics to Present at Jefferies Global Healthcare Conference in London - The Manila Times
Candel Therapeutics, Inc. CEO Paul Peter Tak to Present at Jefferies Global Healthcare Conference 2025 - Quiver Quantitative
Will Candel Therapeutics Inc. see short term momentumJuly 2025 Volume & Capital Efficient Trading Techniques - newser.com
What technical models suggest about Candel Therapeutics Inc.’s comebackTrade Entry Report & Expert Curated Trade Setup Alerts - newser.com
Is Candel Therapeutics Inc. building a consolidation baseJuly 2025 Market Mood & Weekly Momentum Picks - newser.com
How Candel Therapeutics Inc. stock compares to growth peersJuly 2025 Drop Watch & Expert Curated Trade Setup Alerts - newser.com
Intraday pattern recognizer results for Candel Therapeutics Inc.2025 Risk Factors & Daily Chart Pattern Signals - newser.com
What’s next for Candel Therapeutics Inc. stock priceOil Prices & Detailed Earnings Play Strategies - newser.com
Can Candel Therapeutics Inc. stock sustain revenue growth2025 Top Decliners & Step-by-Step Swing Trade Plans - newser.com
Why analysts upgrade Candel Therapeutics Inc. stockJuly 2025 Recap & Accurate Buy Signal Notifications - newser.com
Will Candel Therapeutics Inc. stock outperform international peersMarket Movement Recap & Free Technical Pattern Based Buy Signals - newser.com
Will Candel Therapeutics Inc. stock benefit from automationLong Setup & Real-Time Stock Entry Alerts - newser.com
Finanzdaten der Candel Therapeutics Inc-Aktie (CADL)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.45%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):